GlassScriptPhysician profile
Neha Russo
NPI 1063950665
$9,823.56
in general payments reported to CMS, 2019-2025
33 companies · $2,395 in 2025
The $2,395 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,296 · 2022: $1,972 · 2023: $1,908 · 2024: $2,254 · 2025: $2,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,345 · Consulting Fee: $116 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,344.93 |
| Consulting Fee | $116.34 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,364.47 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,138.56 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $1,005.11 | 2021-2025 | Tezspire |
| Csl Behring | $891.54 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $618.95 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $593.68 | 2021-2025 | Cuvitru, Eohilia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $338.06 | 2021-2024 | Dupixent |
| Pfizer INC. | $326.94 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $271.88 | 2021-2025 | |
| Genentech USA, INC. | $267.02 | 2021-2025 | Xolair |
| Pharming Healthcare, INC. | $257.67 | 2022-2025 | Joenja, Ruconest |
| Grifols USA, LLC | $182.74 | 2022-2024 | Xembify |
| Sanofi-Aventis U.S. LLC | $171.98 | 2022-2024 | |
| Abbvie INC. | $152.74 | 2024 | |
| Alk-Abello, INC | $151.92 | 2022-2025 | Ragwitek, Odactra, Grastek |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $140.03 | 2021-2023 | Auvi-Q |
| Adma Biomanufacturing LLC | $116.34 | 2023-2025 | |
| Octapharma USA, INC. | $113.95 | 2022-2025 | Panzyga |
| Optinose US, INC. | $108.99 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $106.62 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $88.21 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.58 | 2021-2022 | |
| Bio Products Laboratory USA, INC. | $67.28 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $49.93 | 2023-2024 | Orladeyo |
| Aimmune Therapeutics, INC. | $46.54 | 2022 | |
| Phadia US INC. | $36.75 | 2022 | |
| Blueprint Medicines Corporation | $26.35 | 2023 | Ayvakit |
| Leo Pharma INC. | $21.26 | 2022 | |
| Organon LLC | $20.66 | 2025 | |
| Galderma Laboratories, L.P. | $16.31 | 2025 | Nemluvio |
| Allergan, INC. | $16.20 | 2022 | |
| Hospira, INC. | $14.60 | 2024 | |
| Dermavant Sciences, INC. | $13.70 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.